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https://doi.org/10.1016/j.cell.2021.06.002SUMMARYMonoclonal antibodies against SARS-CoV-2 are a clinically validated therapeutic option against COVID-19.
Because rapidly emerging virus mutants are becoming the next major concern in the fight against the global
pandemic, it is imperative that these therapeutic treatments provide coverage against circulating variants
and do not contribute to development of treatment-induced emergent resistance. To this end, we investi-
gated the sequence diversity of the spike protein and monitored emergence of virus variants in SARS-
COV-2 isolates found in COVID-19 patients treated with the two-antibody combination REGEN-COV, as
well as in preclinical in vitro studies using single, dual, or triple antibody combinations, and in hamster in vivo
studies using REGEN-COV or single monoclonal antibody treatments. Our study demonstrates that the com-
bination of non-competing antibodies in REGEN-COV provides protection against all current SARS-CoV-2
variants of concern/interest and also protects against emergence of new variants and their potential seeding
into the population in a clinical setting.INTRODUCTION
The coronavirus disease 2019 (COVID-19) global pandemic has
motivated a widespread effort to understand adaptation of its
etiologic agent, the severe acute respiratory syndrome coronavi-
rus 2 (SARS-CoV-2). Similar to all viruses, SARS-CoV-2 is
constantly evolving; mutants are selected due to a fitness advan-
tage, which can be associated with an ability to spreadmore effi-
ciently in the human population or to overcome natural or vac-
cine-mediated immune responses. Ongoing viral evolution is a
major concern for direct antivirals, especially for therapeutics
targeting the main proteins recognized by humoral immunity,
such as the viral glycoproteins. Such mutations can provide a
fitness advantage in the context of drug treatment; therefore
they can be rapidly selected during therapy and may lead to
treatment failure and/or spread of treatment resistant-associ-
ated variants. To date, multiple studies have investigated the
development of viral resistance against neutralizing monoclonal
antibodies (mAbs) targeting the SARS-CoV-2 spike protein
(Baum et al., 2020a; Liu et al., 2021b; Weisblum et al., 2020).Cell 184, 1–1
This is an open access article under the CC BY-NHowever, better understanding of virus evolution as the virus
spreads in humans and the mechanisms driving resistance dur-
ing treatment is necessary to ensure optimal efficacy of
antivirals.
REGEN-COV (previously known as REGN-COV2) is a cocktail
of two fully human non-competing, neutralizing antibodies—ca-
sirivimab (REGN10933) and imdevimab (REGN10987)—that
target the receptor binding domain (RBD) on the SARS-CoV-2
spike protein and thereby prevent viral entry into the host cell
(Hansen et al., 2020). The strategic decision to include a pair of
highly potent non-competing antibodies that can simultaneously
bind to distinct, non-overlapping epitopes of the RBD was made
to safeguard against the rapid emergence of drug-resistant var-
iants and provide coverage against circulating viral variants
(Baum et al., 2020a). In vitro studies showed that combining
two non-competing antibodies protected against rapid escape
seen with its individual single-antibody components (Baum
et al., 2020a). Additionally, the benefit of this combination
approach has been supported by subsequent studies showing
that REGEN-COV retains neutralization potency against3, July 22, 2021 ª 2021 The Author(s). Published by Elsevier Inc. 1
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
(legend on next page)
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increased infectivity (e.g., D614G and UK B.1.1.7 variants), as
well as those associated with reduced vaccine-induced neutral-
ization titers or vaccine efficacy (e.g., South Africa B.1.351), even
when one of its components has partially reduced activity (Gar-
cia-Beltran et al., 2021; Liu et al., 2021a; Madhi et al., 2021;
Wang et al., 2021; Yurkovetskiy et al., 2020). Concerns regarding
single antibody approaches in the clinic are emerging, based on
increasing prevalence of naturally circulating variants resistant to
these single agents (Wang et al., 2021), and reports within clinical
studies that single antibody treatment is associated with the
emergence of resistant (Food and Drug Administration, 2021).
Although in vitro escape studies using recombinant viruses
strongly support the rationale of using non-competing antibody
combinations to avoid drug resistance, questions remain
regarding the relevance of these findings to authentic SARS-
CoV-2 virus, to in vivo infection models, and most importantly, to
the clinical setting. In this work, we first show that in vitro escape
variantsare rapidly selectedagainst all individual clinical-stagean-
tibodies targeting the RBDof the spike protein, independent of the
targeted epitope or its degree of conservation, that such risk can
bemitigated by utilizing combinations of two non-competing anti-
bodies, and even further reduced by combining three non-
competing antibodies. We extend these findings by showing that
escape variants can also be efficiently selected in vivo upon treat-
ment with individual antibodies, independent of dosage or treat-
ment setting (prophylaxis or therapy), whereas the REGEN-COV
combination fully protects against development of such resis-
tance. Importantly,weconfirm thesefindings inhumans;we inves-
tigated thegeneticdiversity of theentire spikeproteinacross4,882
samples from 1,000 outpatients or hospitalized patients with
confirmed COVID-19 from ongoing phase 1–3 trials (Weinreich
et al., 2020, 2021; https://clinicaltrials.gov; NCT04666441,
NCT04426695, and NCT04452318). Analysis of baseline and
post-treatment sequence diversity in placebo and REGEN-COV-
treated patients demonstrated that the non-competing antibody
combination protects against selection of drug resistant variants.
RESULTS
We previously generated a large library of fully human mono-
clonal antibodies targeting the spike protein of SARS-CoV-2
and selected REGN10933 + REGN10987 as a pair of potently
neutralizing molecules that can simultaneously bind to their
target (Hansen et al., 2020). We hypothesized that this non-
competing antibody combination would retain its potency as
the virus evolves in the human population and safeguard against
selection of escape mutants following treatment (Baum et al.,
2020a; Tegally et al., 2020)
With the recent rise in rapidly emerging variants, we are able to
test this hypothesis by evaluating the potency of the individualFigure 1. Neutralization of variants of concern and variants of interest
Neutralization curves and (A) Neutralization fold-decrease (B) relative to parent
D614G, P681H, T716I, S982A, D1118H), South African B.1.351 (D80Y, D215Y, L2
P.1 (L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y
California (L452R) and B.1.617.1 India (L452R/E484Q) and B.1.617.2 India (L452R
global lineages, including the B.1.526 New York, P.2 Brazil and B.1.618 India linantibodies as well as the REGEN-COV combination against var-
iants of concern/interest as defined by the Centers for Disease
Control and Prevention (CDC), including B.1.1.7 (UK), B.1.427/
B.1429 (California), B.1.351 (South Africa), P.1 (Brazil), B.1.526
(New York), and B.1.617.1/B.1.717.2/B.1.617.3 (India) lineages
(Centers for Disease Control and Prevention, 2021; Davies
et al., 2021; Nonaka et al., 2021; Tegally et al., 2020; West
et al., 2021; Zhang et al., 2021) Importantly, even in instances
where one of the antibodies is impacted, the combination retains
full neutralization potency, a key property through which this
combination of antibodies was originally selected, thusmaintain-
ing coverage against all assessed variants (Figures 1A and 1B).
We have previously shown that combination therapy with two
anti-spike antibodies targeting non-overlapping epitopes of the
SARS-CoV-2 spike protein minimizes the likelihood of rapid viral
escape observed in vitrowith monotherapy (Baum et al., 2020a),
as has also been demonstrated by others (Dong et al., 2021;
Weisblum et al., 2020). Expanding on our previous work using
VSV-SARS-CoV-2-spike recombinant virus to monitor resis-
tance tomAb treatment, we now performed such escape studies
with several RBD-targeting mAbs approved under emergency
use authorization (EUA) or in late-stage clinical trials and tested
monotherapy as well as dual and triple combinations. We found
that although only one to two passages led to complete virus
resistance against all mAbs used as monotherapy, seven
consecutive passages were needed to reach complete resis-
tance to the REGEN-COV combination, requiring selection of
multiple simultaneous mutations impacting each antibody (Fig-
ures 2A and 2B). Escape variants identified with COV2-2130,
COV2-2196, and LY-COV555 antibodies were consistent with
those previously described for these molecules (Table S1;
Dong et al., 2021; Food and Drug Administration, 2021). Similar
to the REGEN-COV combination, the COV2-2130 and COV2-
2196 cocktail was also resistant to rapid escape, and full escape
was associated with acquiring multiple mutations within the
same virus (Figure 2A) (Dong et al., 2021). In contrast, the LY-
CoV555/CB6 combination behaved similarly to monotherapy,
where rapid escape driven by a single amino acid substitution
was observed. Such rapid escape from combinations of
competing antibodies has been demonstrated in our previous
studies and is expected based on the overlapping nature of
the LY-CoV555 and CB6 epitopes (Baum et al., 2020a; Jones
et al., 2021; Shi et al., 2020; Starr et al., 2021).
Importantly, rapid escape observed in the monotherapy
setting was independent of the targeted epitope or its sequence
conservation because escape variants were rapidly selected
against an antibody targeting a broad coronavirus epitope,
VIR-7831 (Pinto et al., 2020; Figure 2A; Table S1). All VIR-7831
escape residues mapped to the published epitope of the anti-
body, and the resultant escape virus maintained its ability to
replicate, indicating that these mutations were not deleteriousby the REGEN-COV combination and individual antibodies
al D614G variant. Full UK B.1.1.7 (H69del, V70del, Y145del, N501Y, A570D,
41del, L242del, A243del, L242del, K417N, E484K, N501Y, D614G, A701V) and
, T1027I, V1176F) variants were assessed. Key RBD residues from B.1.429
/T478K) variants were assessed. The E484K variant has been identified inmany
eages. Data represent three technical replicates.
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Figure 2. In vitro escape with individual an-
tibodies and antibody combinations
VSV-spike recombinant viruswas passaged under
pressure of individual antibodies or antibody
combinations.
(A) Passage number during which the virus
completely escaped neutralizing activity of the
antibodies as evidenced by the cytopathic effect
(CPE) is shown as ‘‘complete escape’’ for wells
where antibody concentration was 10 mg/mL or
above or ‘‘partial escape’’ for wells where antibody
concentration was 1–10 mg/mL.
(B) Neutralization potency of the two mAb
REGN10987+REGN10933 combination and
the three mAb REGN10987+REGN10933+
REGN10987+REGN10985 combination along
with individual mAbs. Data represent three
technical replicates.
(C) Two views of the RBD-REGN10933-
REGN10987-REGN10985 model. RBD is colored
white; REGN10933 is shown blue, REGN10987 is
shown in red and REGN10985 is shown in green.
Surface representation of the RBD in white with
contact patches for each antibody, colors as in (A).
See also Figure S4 and Table S1.
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Articleto the virus (data not shown). Furthermore, the identified escape
variants can be found in publicly available genome sequences
(GISAID), indicating that they are tolerated by the authentic
SARS-CoV-2 virus and thus are likely to be selected under pres-
sure. These experiments highlight the inherent risk of monother-
apy against SARS-CoV-2 with any anti-spike mAb, regardless of
the targeted epitope or its conservation.
We have previously described a triple antibody combination
against Zaire ebolavirus (Pascal et al., 2018), and we similarly
decided to assess potential advantages of combining three non-
competing neutralizing mAbs targeting the RBD of SARS-CoV-
2:REGN10933+REGN10987+REGN10985. As part of an effort to4 Cell 184, 1–13, July 22, 2021structurally characterize our SARS-CoV-
2 neutralizing antibodies, we determined
a cryoelectron microscopy (cryo-EM)
structure of REGN10985 (plus another
antibody, REGN10989) bound to RBD
(Figure S1). REGN10985 binds to a broad
patch on the side of the RBD, directly
below the region contacted by ACE2.
Although there is very little overlap be-
tween the ACE2 and REGN10985 contact
surfaces on theRBD, theREGN10985 Fab
is angled so that it overlaps with the space
that ACE2would occupy,making this anti-
body a direct blocker of ACE2 binding
like REGN10933 and REGN10987. By
combining this cryo-EM structure with
our previously determined structure of
REGN10933+REGN10987+RBD (Hansen
et al., 2020), we produced a model of the
three-antibody complex showing that all
three mAbs are able to bind simulta-neously to the RBD of the spike protein in a non-overlapping
fashion (Figure 2C). We additionally demonstrated that the
three-antibody combination has similar neutralization potency
as REGEN-COV (Figure 2B). We found that addition of the third
non-competing RBD mAb further increased protection against
viral escape, with no loss of antiviral potency observed through
eleven consecutive passages (Figure 2A; Table S1). These results
demonstrate that a three-mAb neutralizing non-competing com-
bination targeting the spike RBD provides a potential further
advantage as a SARS-CoV-2 therapeutic.
Tounderstandhow these in vitroescapefindingsdemonstrating
thatmAb combination treatments safeguard against development
(legend on next page)
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Articleof drug resistance translate to a more physiological setting, we
evaluated virus evolution in vivo following mAb administration as
both monotherapy (REGN10987 or REGN10933) and as the RE-
GEN-COV combination in the SARS-CoV-2 hamster challenge
model. Animals were challenged with SARS-CoV-2 (USA-WA1/
2020) and treated with either high or low dose (50 mg/kg or
5 mg/kg) of either REGN10987 or REGN10933 as monotherapy
or with the REGEN-COV combination (50 mg/kg or 5 mg/kg) in
both prophylactic and treatment settings (Figure 3A). These doses
were previously shown to provide partial or complete efficacy in
this animal model with REGEN-COV (Baum et al., 2020b). Lungs
from infectedanimalswerecollectedonday7post-challenge,pre-
sumably after the virus has had an opportunity to go through mul-
tiple rounds of replication, to isolate viral RNA. RNA sequencing
(RNA-seq) analysiswas used todetect variants in the spike protein
present even at low frequencies in the virus population (>5%). To
identify putative treatment resistant variants, we focused our anal-
ysis on the spike RBD, where the REGEN-COV antibodies are
known to bind andwhere all previously identified resistant variants
to either antibodyare located.Analysis of theRBDsequence in sa-
line-treated animals did not reveal any variants, indicating that in
the absence of treatment the virus is not under strong selection
pressure in this model (Figures 3B and 3C). However, several var-
iants in theRBDwere identified in animals treatedwith either of the
single antibodies as monotherapy (Figures 3B and 3C). Remark-
ably, our analysis demonstrated selection of resistance variants
in almost half (18/40) of monotherapy-treated animals versus
none (0/20) of the animals treatedwith the REGEN-COV combina-
tion. Out of the 7 RBD variants identified in monotherapy-treated
animals, 6 have been previously described as resistance variants
or mapped to the same amino acid position as other resistance
variants to either REGN10933 or REGN10987 (Table S3). Four of
these variants were previously identified in our in vitro escape
studies, validating the relevance of using VSV-SARS-CoV-2-spike
recombinant virus to identify SARS-CoV-2 escape mutations
(Baum et al., 2020a). Interestingly, variant selection occurred
with monotherapy treatment in both the prophylactic and thera-
peutic settings, and in both low and high dose groups. Although
rareuniquevariantsoutsideof theRBDwerealso identified inasin-
gle animal treated with the REGEN-COV combination (Figures 3B
and 3C), the low frequency of these variants and their locationwell
outside the epitopes of the antibodies make it extremely unlikely
that they were associated with the REGEN-COV treatment.
To assess the emergence of drug resistance in REGEN-COV-
treated COVID-19 patients, we characterized the genetic diver-
sity of 1,336 and 3,546 SARS-CoV-2 RNA samples isolated
from 272 hospitalized and 728 non-hospitalized individuals,
respectively, at baseline and several time points post mAb
cocktail administration (Table S2). In both hospitalized and
non-hospitalized study groups, patients were randomly as-Figure 3. Frequency of SARS-CoV-2 spike variants identified in viruses f
as monotherapy or with the REGEN-COV combination in both prophyla
(A) Study design (n = 5 for placebo group, n = 10 for treatment groups).
(B andC) Graphs show the distribution and frequencies of amino acid variants acro
(C) treated groups. Mutated sites are indicated with gray lines and dots show the
used. Spike protein domain is color coded as indicated, and all amino acid chan
See also Table S3.
6 Cell 184, 1–13, July 22, 2021signed (1:1:1) to receive placebo, 2.4 g of REGEN-COV, or
8.0 g of REGEN-COV, and patient samples were collected at
multiple time points from baseline (day 1) to study end point
(day 29). RNA-seq analysis was performed to characterize the
genetic diversity of the spike sequence from all swabs positive
for SARS-CoV-2 RNA by qRT-PCR. Minor variants present at a
frequency of at least 15% in the virus population were identi-
fied. In total, 244 and 514 amino acid changes were identified
across all samples from hospitalized and non-hospitalized pa-
tients, respectively. For both studies, variant counts and fre-
quencies in all three treatment groups were similar, indicating
that REGEN-COV did not increase spike protein diversity rela-
tive to placebo (Table S2).
To determine whether REGEN-COV treatment contributed to
selection of resistant variants in the spike protein, we longitudi-
nally compared the frequency of minor variants in each patient
from all available RT-PCR-positive samples. Among all patient
samples from the hospitalized group, we identified a total of
89, 87, and 108 amino acid changes in the placebo, low dose-,
and high dose-treated groups, respectively. These mutations
were evenly spread across the entire spike protein sequence
(Figures 4A and 4B). The low number of variants in the RBD found
among samples from patients treated with REGEN-COV further
demonstrated lack of treatment emergent selection relative to
placebo (15 RBD variants in placebo versus 12 low-dose/12
high-dose in REGEN-COV-treated group). Only 17% (42/244)
of all amino acid changes were observed at more than one
time point in at least one patient (Figure 4B) indicating that the
vast majority of variants were lost over time likely as a result of
lack of fitness or population bottlenecks. Three of these variants
were found in the RBD in the REGEN-COV-treated groups only
(S477N, N501T, and K537R). The S477N variant was present in
7 REGEN-COV-treated patients at multiple time points, including
baseline (Figure S2). S477N is a common SARS-CoV-2 variant
present at a frequency of >5% viruses circulating worldwide
(source: GISAID). K537R was identified in 1 treated patient and
is a raremutation, which has been found in only <10 virus isolates
worldwide to date (Figure 5, source: GISAID). N501T was
observed in 3 treated patients in this study (Figure 5). Of note,
in all patients, the three variants were identified at baseline or
earliest time points (<5 days after REGEN-COV treatment), and
no significant increase in their frequencies between early and
late time points were observed indicating absence of treat-
ment-related selection.
We identified a total of 216, 248, and 212 amino acid changes
among the 1,215 placebo, 1,203 low-dose, and 1,128 high-dose
REGEN-COV-treated patient samples, respectively, from the
non-hospitalized group, spread across the entire spike protein
sequence (Figure 6). The RBD contained, respectively, 23, 27,
and 31 amino acid changes among which S477N and only 2rom lungs of hamsters treatedwith either REGN10987 or REGN10933
ctic and treatment settings
ss the spike protein sequence identified in samples from the (B) prophylactic or
frequency of variants in each animal. The color of each dot indicated the dose
ges in RBD are labeled. Study represents one biological replicate.
Figure 4. Variant analysis of virus sequences in SARS-CoV-2-positive samples from hospitalized patients
Graphs show the distribution of amino acid variants across the spike protein sequence identified in samples from the placebo, REGEN-COV low dose-, and
REGEN-COV high dose-treated patients. Mutated sites are indicated with arrows, and arrow length designates the number of patients with 1 or more variant-
containing samples. Spike protein domains are color coded as indicated and all amino acid changes in RBD are labeled.
(A) Arrows highlight variants identified in 1 or more samples from at least one patient.




Please cite this article in press as: Copin et al., The monoclonal antibody combination REGEN-COV protects against SARS-CoV-2 mutational
escape in preclinical and human studies, Cell (2021), https://doi.org/10.1016/j.cell.2021.06.002
Articleother variants (S494P and G446V) were identified at more than
one time point in at least one REGEN-COV-treated patient (Fig-
ure 6B). The S477N variant was present in 3 REGEN-COV- and 5
placebo-treated patients at multiple time points, including base-
line (Figure S3). S494P is a rare circulating mutation (0.15%GI-
DAID) only found at multiple time points (including baseline) in 2
REGEN-COV-treated patients. G446V is a rare variant (0.02%
GISAID) identified in 4 REGEN-COV-treated and 2 placebo pa-
tients (Figure 7). One of these patients (Figure 7, patient B4), rep-
resented the only example with a consistent late increase in the
relative frequency of the variant, however, it should be pointed
out that there is no evidence that the absolute frequency of the
variant increased over time as viral levels dropped dramatically
over time. For all G446V patients, including patient B4, we
observed that the frequency of variants was decreased to unde-tectable at the latest time points, indicating that drug-mediated
selection is unlikely.
To determine the functional impact of RBD variants identified
at multiple time points in REGEN-COV-treated patients, individ-
ual antibodies and the combination were assessed for neutrali-
zation potency against the G446V, S494P, S477N, and K537R
variants (Figure S4). Decrease in neutralization potency was
observed with REGN10987 (135-fold) against the G446V variant,
and minimally with REGN10933 (4.5-fold) against the S494P
variant, whereas no impact was observed on either mAb with
the S477N or K537R variants. The N501T variant was not as-
sessed but an alternative substitution N501Y did not show any
impact on either antibody or the REGEN-COV combination.
Importantly, in all instances the REGEN-COV combination re-
tained full neutralization potency, thereby providing its fullCell 184, 1–13, July 22, 2021 7
Figure 5. Viral load and longitudinal frequencies of variants in REGN-COV2-treated, SARS-CoV-2-positive samples from hospitalized
patients
Viral load was determined by quantitative RT-PCR. N501T (A) and K537R (B) variant frequencies are indicated by the black line as percent of reads with nSNPs
relative to total number of covering reads. Histograms show total (blue) andmutated (magenta) read coverage at variant position. See also Figures S1 and S3 and
Tables S2 and S4.
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selection of resistant variants.
DISCUSSION
The increasing use of mAbs as a clinically validated therapeutic
option against SARS-CoV-2 raises questions about which of
these therapies may be impacted by circulating and rapidly8 Cell 184, 1–13, July 22, 2021emerging variants and which may induce treatment-emergent
resistance. The recent recognition that some immunodominant
residues in the spike protein, such as E484K, often impact
both mAb therapies and vaccine-induced immune responses
makes it imperative to ensure that mAb treatments not only pro-
vide protection against common circulating variants but to also
ensure that treatment-induced escape variants are not seeded
into the population, where they may contribute to undermining
Figure 6. Variant analysis of virus sequences in SARS-CoV-2-positive samples from non-hospitalized patients
Graphs show the distribution of amino acid variants across the spike protein sequence identified in samples from the placebo, REGEN-COV low dose-, and
REGEN-COV high dose-treated patients. Mutated sites are indicated with arrows, and arrow length designates the number of patients with 1 or more variant-
containing samples. Spike protein domains are color coded as indicated and all amino acid changes in RBD are labeled.
(A) Arrows highlight variants identified in 1 or more samples from at least one patient.
(B) Arrows highlight variants identified in 2 or more samples from at least one patient. All samples were characterized by the defining glycine substitution at
position 614.
See also Figures S2 and S3 and Tables S2 and S4.
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Articleefficacy of other therapeutics or vaccines (Greaney et al., 2021;
Wang et al., 2021). Real-world manifestations of such concerns
are demonstrated by the recent withdrawal of emergency use
authorization of bamlanivimab monotherapy due to high preva-
lence of the B.1.526 and B.1.427/B.1429 variants, as well as
the recent US government recommendation against the use of
the bamlanivimab/estevimab combination in Illinois and Massa-
chusetts due to high prevalence of the P.1 variant, which impacts
both antibodies in the combination (U.S. Department of Health
and Human Services, 2021a, 2021b).
To date, we and others have identified antibody resistant var-
iants through in vitro escape studies and have demonstrated that
combinations of two non-competing antibodies provide protec-
tion against rapid viral escape (Baum et al., 2020a; Weisblum
et al., 2020). We hypothesized that a cocktail of three non-
competing antibodies could further delay emergence of resis-
tance. Although neutralizing antibodies against the N-terminal
domain (NTD) of spike has been described (Liu et al., 2020),
this region is frequently deleted in emerging variants (Wanget al., 2021), and therefore such molecules are not ideal as ther-
apeutics. We thus screened for, and identified, a third, non-
competing, RBD-binding mAb and now show that a triple anti-
body combination containing this mAb is even less susceptible
to escape than the double combination.
However, the question regarding the relevance of these in vitro
escape studies remains, and it is important to examine viral dy-
namics under therapeutic antibody pressure in more relevant
settings, including in in vivo efficacy models and in treated pa-
tients. Our study provides evidence that in vitro escape studies
with recombinant virus are highly predictive of in vivo selection.
Indeed, we are able to show that in animals and in humans, the
relative risk of selecting for spike variants that are resistant to
treatment is predicted by in vitro findings. Treatment with the
single antibody components of the REGEN-COV combination
results in rapid selection of escape variants, whereas the combi-
nation protects against viral escape in vitro, in vivo, and in
COVID-19 patients. Furthermore, by comparing escape muta-
tions identified through in vitro assays utilizing recombinantCell 184, 1–13, July 22, 2021 9
Figure 7. Viral load and longitudinal frequencies of variants in SARS-CoV-2-positive samples from non-hospitalized patients
Viral load was determined by quantitative RT-PCR. S494P (A) and G446V (B) variant frequencies are indicated by the black line as percent of reads with nSNPs
relative to total number of covering reads. Histograms show total (blue) and mutated (magenta) read coverage at variant position. See also Tables S2 and S4.
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ArticleVSV-based virus to those identified in SARS-CoV-2 infected
hamsters, we show that many identical mutations are identified
in both settings, further validating the in vitro findings.10 Cell 184, 1–13, July 22, 2021Understanding pathogen population diversity and selection
within the infected host has important implications for under-
standing virus evolution and resistance processes and for proper
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Articleidentification of appropriate drug treatments. To date, the vast
majority of SARS-CoV-2 sequencing data has come from global
surveillance efforts and reporting of consensus sequences that
include fixedmutations in isolates obtained from independent in-
dividuals. This is a large-scale report describing, within individual
patients, the longitudinal evolution of the SARS-CoV-2 virus
population. Moreover, this study evaluates the effects of antiviral
antibody treatment on virus evolution in humans. As predicted by
our in vitro and in vivo preclinical studies, treatment with the RE-
GEN-COV cocktail in the clinic did not seemingly select for resis-
tant variants nor appreciably alter virus evolution. Our approach
allowed us to observe minor variants, and our data indicate the
vast majority of infected individuals are already harboring spike
protein variants at baseline, prior to use of any antiviral agent
and before natural immunity is established, as half of the study
participants had not yet mounted an antiviral immune response
at baseline (Weinreich et al., 2020). Indeed, from our clinical
sequencing data, we can observe multiple variants in amino
acid residues identified in our in vitro escape studies expected
to impact clinical antibody candidates, including VIR-7831
(P337, T345) and COV-2196 (G476) as well as our own individual
antibodies. This clearly demonstrates that the SARS-CoV-2
circulating population is highly heterogeneous in infected pa-
tients and the large reservoir of existing (or future) minor variants
could be readily selected under the right selective pressure con-
ditions. Indeed, treatment-emergent resistant variants have
been reported in clinical studies in which patients were treated
with anti-SARS-CoV-2 antibody monotherapy (FDA, 2021).
Although the REGEN-COV combination maintains its neutral-
ization potency against all variants of interest/concern to date,
one of its components (REGN10933) demonstrates partially
decreased potency against some variants. This highlights the
potential risk that even non-competing combination therapies
may not retain their full advantages in some geographical regions
with high prevalence of select variants of concern. Thus, active
surveillance of circulating viruses and development of next-gen-
eration antibody combinations where multiple components
maintain coverage against emerging variants should be an
important focus for the future of antiviral mAb therapeutics.
This type of approach will require agility and may need to be
analogous to the framework applied to seasonal updates of influ-
enza vaccine components, where new anti-spike mAbs are
substituted or added as necessary to maintain optimal efficacy
against a rapidly mutating pathogen.
To ensure optimal and sustained efficacy, an antiviral thera-
peutic intervention should be prospectively designed to not
only have coverage against major circulating variants, but also
to prevent the selection of minor escape variants. Although the
risk of viral resistance cannot be completely eliminated, it can
be greatly reduced through selection of optimal combination
therapies. This study demonstrates that carefully designed anti-
body combinations can achieve both of these critical objectives.
LIMITATIONS OF THE STUDY
The current study focused on assessing the likelihood of identi-
fying REGEN-COV-mediated selection of resistant viral variants
in treated COVID-19 patients and overall predictability of preclin-ical in vitro and in vivo escape studies to human patients. Our
data clearly demonstrated that treatment with any RBD-directed
mAb monotherapy results in rapid selection of drug-resistant
viral variants. However, althoughwe did not identify any clear se-
lection of resistant variants in the clinical population after treat-
ment with REGEN-COV, it was impossible for us to directly
compare monotherapy and combination therapy in the clinical
setting due to the combination nature of our therapeutic. Thor-
ough sequencing of viral samples post-treatment with clinical
monotherapy products may help to provide clinical data on likeli-
hood of resistance in that setting. Furthermore, although we as-
sessed over 3,000 samples from 1,000 patients in our study to
identify potential REGEN-COV-associated selection of variants,
it is possible that this sample size may not be large enough to
identify very rare events.
STAR+METHODS
Detailed methods are provided in the online version of this paper
and include the following:
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clinical trial in hospitalized patients with Covid-19 (https://clinicaltrials.gov: NCT04426695). Hospitalized patients > 18 years of agee3 Cell 184, 1–13.e1–e7, July 22, 2021
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receive placebo, 2.4g (1.2 g each of casirivimab and imdevimab) or 8.0 g (4.0 g each of casirivimab and imdevimab). For the present
work, 968 nasopharyngeal, 249 nasal and 119 saliva samples retrieved from a total of 272 patients were analyzed. Sex/gender of
human donors was not associated with the samples.
Animals
A total of 80 golden hamsters, male, approximately 9 weeks of age (130-150 g) were used in the study. Animals were housed one to
five per cage; caging complies with the cage requirements (type, floor space, height, etc.) of the Animal Welfare Act and the Guide for
the Care and Use of Laboratory Animals. Animals were acclimated to ABSL-3 laboratory conditions prior to exposure. In the ABSL-3,
prior to virus exposure, animals were observed at least once daily, and after virus exposure animals were observed at least twice daily
for morbidity and mortality. On Day 2 relative to exposure, animals were sedated and received treatment via intraperitoneal
injection.
Cells
African green monkey kidney cells (Vero, ATCC CCL-81), Vero clone E6 (Vero E6, ATCC CRL-1586), and human embryonic kidney
cells (293T, ATCC CRL-3216), were maintained at 37C and 5% CO2 and cultured in high glucose Dulbecco’s Modified Eagle’s Me-
dium without glutamine (DMEM; Life Technologies) supplemented with 10% fetal bovine serum (FBS; Life Technologies) and 1%
Penicillin/Streptomycin/L-glutamine (Life Technologies).
Viruses
SARS-CoV-2 generated from isolate USA-WA1/2020 was used for animal exposures. A fourth cell-culture passage (P4) of SARS-
CoV-2 was obtained from Biodefense and Emerging Infections Research Resources Repository (BEI Resources, catalog number
NR-52281, GenBank accession number MN985325.1) and propagated at Texas Biomed, under Biosafety Level (BSL) – 3 conditions.
The stock virus was passaged for a fifth time in Vero E6 cells at a multiplicity of infection (MOI) of approximately 0.001. This master
stock was used to generate a sixth cell culture passage exposure stock by infecting VeroE6 cells at an MOI of 0.02. The resulting
stock had a titer of 1.2 3 106 PFU/mL. The exposure stock has been confirmed to be SARS-CoV-2 by deep sequencing and was
identical to the published sequence (MN985325.1) at the consensus level.
METHOD DETAILS
Generation of recombinant VSV
Non-replicative pseudoparticles were generated using a VSV genome encoding the firefly luciferase and GFP genes instead of the
native viral glycoprotein (VSV-G). Infectious particles complemented with VSV-G (VSV-DG-Fluc-2A-GFP/VSV-G) were recovered
and produced using standard techniques with minor modifications (Baum et al., 2020a; Hansen et al., 2020; Lawson et al., 1995).
HEK293T cells (ATCC CRL-3216) were plated on poly-lysine treated plates and incubated overnight in DMEM without glutamine
(Life Technologies), 10% fetal bovine serum (Life Technologies) and 1% Penicillin/Streptomycin/L-glutamine (Life Technologies).
The following day, the cells were transfected with the VSV genomic clone driven by a T7 promoter and helper plasmids expressing
the VSV-N, VSV-P, VSV-G, VSV-L, and T7 RNA polymerase with Lipofectamine LTX reagent (Life Technologies). After 48 hours, the
transfected cells were co-cultured with BHK-21 cells (ATCC CCL-10) transfected with VSV-G using the SE cell Line 4D-Nucleofector
X Kit L (Lonza) in DMEM without glutamine (Life Technologies), 3% fetal bovine serum (Life Technologies) and 1% Penicillin/Strep-
tomycin/L-glutamine (Life Technologies). Cells weremonitored for GFP expression or cytopathic effect (CPE) indicative of virus repli-
cation. Virus was then plaque purified, expanded, and titered in BHK-21 cells transiently expressing VSV-G. Fully replicative VSV-
SARS-CoV-2-S virus was generated by replacing the VSV glycoprotein with the native SARS-CoV-2 sequences encoding residues
1-1255 of the spike protein (MN908947.3). VSV-SARS-CoV-2-Spike virus was recovered as described above but the HEK293T cells
were instead cocultured with BHK-21 cells transfected with both VSV-G and hACE2. VSV-SARS-CoV-2-S virus was plaque purified
and titered in Vero cells (ATCC CCL-81) and expanded in Vero E6 cells (ATCC CRL-1586). After collection, stocks of both viruses
were centrifuged at 3000xg for 5 minutes to clarify, sucrose cushioned to concentrate 10-fold, aliquoted, and frozen at 80C.
Pseudotyping of VSV
Non-replicative pseudoparticles were generated as previously described (Baum et al., 2020a). Human codon-optimized SARS-CoV-
2 spike (MN908947.3) was cloned into an expression plasmid. A total of 1.2 3 107 HEK293T cells (ATCC CRL-3216) were seeded
overnight in 15-cm dishes in DMEM without glutamine (Life Technologies) containing 10% heat-inactivated fetal bovine serum
(Life Technologies), and Penicillin- Streptomycin-L-Glutamine (Life Technologies). The following day, the cells were transfected
with 15ug spike expression plasmid with Lipofectamine LTX (Life Technologies) following the manufacturer’s protocol. At 24 hours
post transfection, the cells were washed with phosphate buffered saline (PBS) and infected at a MOI of 1 with the VSV-DG-Fluc-2A-
GFP/VSV-G virus diluted in 10mL Opti-MEM (Life Technologies). The cells were incubated 1 hour at 37C with 5% CO2. Cells were
washed three times with PBS to remove residual input virus and overlaid with DMEM with glutamine (Life Technologies) with 0.7%
IgG-free BSA (Sigma), sodium pyruvate (Life Technologies), and Gentamicin (Life Technologies). After 24 hours at 37Cwith 5%CO2,Cell 184, 1–13.e1–e7, July 22, 2021 e4
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80C. Variants were cloned into the spike expression plasmid using site-directed mutagenesis and pseudoparticles were produced
as described above.
Neutralization assays with VSV based pseudoparticles
Vero cells (ATCC: CCL-81) were seeded in 96-well black, clear bottom tissue culture treated plated (Corning: 3904) at 20,000 cells/
well in DMEM media without glutamine (Life Technologies) containing 10% heat-inactivated fetal bovine serum (Life Technologies),
and 1X Penicillin/Streptomycin/L-Glutamine (Life Technologies) 24 hours prior to assay. Cells were allowed to reach approximately
85%confluence before use in assay. Antibodies were diluted in InfectionMedia containing DMEMwith glutamine (Life Technologies),
0.7% Low IgG BSA (Sigma), 1X Sodium Pyruvate (Life Technologies), and 0.5%Gentamicin (Life Technologies) to 2X assay concen-
tration and diluted 3-fold down in Infection media, for an 11-point dilution curve in the assay beginning at 3 ug/mL (20 nM). Antibody
dilutions were mixed 1:1 with pseudoparticles for 30 minutes at room temperature prior to addition onto Vero cells. Cells were incu-
bated at 37C, 5%CO2 for 24 hours. Supernatant was removed from cells prior to lysis with 100 uL Glo Lysis Buffer (Promega). 100 uL
resuspended Bright Glo substrate (Promega) was then added and luminescence was read on a Spectramax i3x (Molecular Devices).
Exported values were analyzed using GraphPad Prism (v8.4.1)
In vitro Escape Studies
Escape studies were performed with recombinant VSV-SARS-CoV-2-Spike virus as previously described (Baum et al., 2020a).
Escape variants were selected by incubating VSV-SARS-CoV-2-Spike under antibody pressure ranging from 0.016ug/mL to
50ug/mL. After 30 minutes of incubation, the mixture was used to infect 2.5x10̂5 Vero (ATCC: CCL-81) or 3x10̂5 Vero E6 (ATCC
CRL-1586) cells at a multiplicity of infection (MOI) of 5. Virus replication was monitored by screening for cytopathic effect over 96
hours. The supernatant and cellular RNAwas collected from thewells with the highest antibody concentration with evident virus repli-
cation. The RNA was then subjected to RNaseq to identify spike protein variants. For subsequent rounds of selection,100uL of su-
pernatant containing the virus was passaged under the same or greater antibody concentrations as in previous passages until com-
plete CPE was observed after antibody treatment at concentration of R 10 ug/mL.
Hamster Study
A total of 80 golden hamsters, male, approximately 9 weeks of age (130-150 g) were used in the study. Animals were weighed prior to
the start of the study. The animals were monitored twice daily for signs of COVID-19 disease (ruffled fur, hunched posture, respon-
siveness, nasal discharge, labored breathing, a.o.) during the study period. Body weights were measured once daily during the study
period. Antibodies were dosed through intraperitoneal (IP) injection (0.200ml volume). Animals were challenged with 1x10̂4 PFU of
(USA-WA1/2020 (NR-52281; BEI Resources) by administration of 0.05ml total of viral inoculum, 0.025ml dropwise into each nostril
(mock exposed animals received the same volume of sterile PBS). Prior to treatment and virus administration, animals were sedated
using inhalational isoflurane. At study end (day 7 post-challenge), animals were euthanized via inhalational CO2 and tissues samples
were aseptically collected for RNaseq. The day 7 time-point was selected for RNA collection and analysis as the virus has had ample
ability to replicate in the animal allowing for detection of selected variants. Tissue samples were inactivated using Trizol Reagent (In-
vitrogen, Carlsbad, CA, USA). All animal studies were conducted in compliance with all relevant local, state, and federal regulations
and were approved by the Texas Biomed Institutional Animal Care and Use Committee (IACUC; protocol number 1739MA).
Clinical Trial Design
Outpatient clinical trial
This is an ongoing adaptive, multicenter, randomized, double-blind, placebo-controlled, seamless phase 1/2/3 clinical trial in COVID-
19 outpatients (https://clinicaltrials.gov: NCT04425629). Non-hospitalized patients > 18 years of age with a SARS-CoV2-positive test
result < 72 hours, and symptom onset < 10 days before randomization, were randomized 1:1:1 to receive placebo, 2.4g (1.2 g each of
casirivimab and imdevimab) or 8.0 g (4.0 g each of casirivimab and imdevimab). The primary virologic endpoint was the timeweighted
average daily change in viral load from baseline (Day 1) through Day 7. The key secondary clinical endpoint was the proportion of
patients with 1 or more Covid-19 related medically-attended visit (MAV) through Day 29.
Hospitalized patient clinical trial
This is an ongoing adaptive, multicenter, randomized, double-blind, placebo-controlled, seamless phase 1/2/3 clinical trial in hospi-
talized patients with Covid-19 (https://clinicaltrials.gov: NCT04426695). Hospitalized patients > 18 years of age with a SARS-CoV2-
positive test result < 72 hours, and symptom onset < 7 days before randomization, were randomized 1:1:1 to receive placebo, 2.4g
(1.2 g each of casirivimab and imdevimab) or 8.0 g (4.0 g each of casirivimab and imdevimab). The primary clinical endpoint was the
incidence of death or required mechanical ventilation through Day 29.
Virus RNA, RT-PCR and Sequencing
Viral RNAwas extracted from hamster samples and from samples collected in the clinical trials (Viracor-Eurofins, MO, USA). RNAlater
Stabilization Solution was aspirated from sample storage tubes, and 1-5mL Qiazol Lysis Reagent (QIAGEN, #79306) was added.e5 Cell 184, 1–13.e1–e7, July 22, 2021
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20C. In preparation for extraction, lysates were thawed, vortexed, and set up on the deck of a Hamilton Robotics Microlab STAR.
The STAR dispensed 150uL of chloroform (Sigma Aldrich, #C2432-500mL) per well to a 2 mL deep well plate (Life Technologies,
#4388476), followed by the addition of either 375 or 750uL of lysate. Additional Qiazol was added to wells where only 375uL lysate
was added to bring the total volume of lysate to 750uL. Robotic 96-channel pipetting was used to mix the Qiazol and chloroform
layers in the deep well plate, followed by a 10 minute incubation at room temperature. The deep well plate was transferred off the
STAR to a High Res Biosolutions NanoCell modular robotic system, then centrifuged for 10 minutes at 18G. The plate was returned
to the STAR, and using robotic 96-channel pipetting, 400 mL clear aqueous phase was aspirated from the top layer of the plate and
transferred to a deep well plate containing 200 mL 100% isopropanol and 10 mL RNA binding beads from the MagMAX-96 for Micro-
arrays Total RNA Isolation Kit (ThermoFisher, #AM1839). The Nanocell system then transferred this plate to a connected KingFisher
Flex. Total RNA was purified on the KingFisher Flex using the aforementioned MagMAX kit, according to manufacturer’s specifica-
tions. 80uL of QIAGEN RNase-Free DNase treatment (QIAGEN, custom order) was substituted for the MagMAX kit DNase treatment.
Once the purification was completed, the elution plate was transferred back to the STAR, and incubated on a PromegaMagnaBot 96
Magnetic Separation Device for 5 minutes to remove residual RNA binding beads. The STAR then transferred 2uL aliquots of the pu-
rified RNA to plates for the Unchained Labs Lunatic and Advanced Analytical Fragment Analyzer. The Lunatic plate reader was used
to obtain concentration and purity data (A260/A280, A260/A230), and the Fragment Analyzer was run with a Standard Sensitivity RNA
Analysis Kit (Advanced Analytical, #DNF-471-1000) for RNA quality data (RQN, 28 s:18 s, and DV200 scores). The remaining RNA
was transferred using robotic 96-channel pipetting to a FluidX 96-format rack and stored at 80C.
Qualitative and quantitative measurements of viral load were determined by quantitative RT-PCR,10 ul of RNA combined with
25 ng Human Universal Reference RNA (Agilent) was purified by PureBeads (Roche Sequencing). cDNA synthesis was performed
using SuperScript IV First-Strand Synthesis System (Thermal Fisher) following vendor’s protocol. Then one half of cDNA (10 ul)
was used to generate libraries using Swift Normalase Amplicon Panel (SNAP) SARS-CoV-2 Panel (Swift Biosciences) following ven-
dor’s protocol. Sequencing was run on NextSeq (Illumina) by multiplexed paired-read run with 2X150 cycles. Overall quality report
was generated summarizing the quality of all reads in each sample, along each base pair.
Variant calling analysis
Swift amplicon bulk RNA-seq reads were aligned to the SARS-COV-2 reference genomeWuhan-Hu-1 (accession: MN908947) using
Minimap2 (v2.17) (Li, 2018). The alignments were sorted by read name, and primers were clipped by the complementary Swiftbio-
sciences primerclip software (v0.3.8) (https://github.com/swiftbiosciences/primerclip). Duplicate reads were removed using the Pic-
ard package (https://github.com/broadinstitute/picard) and target coverage was summarized for each sample with custom scripts.
GATK HaplotypeCaller (v4.1.8) (McKenna et al., 2010) was used to perform single nucleotide polymorphism (SNP) calling. At each
SNP, the frequency of viral mutations inferred from the sequencing reads were calculated from samtools (v1.9) pileup output (Li
et al., 2009). Variants were flagged if nucleotide positions were covered by at least 10 reads and frequency of mutated reads at these
positions was at least 15%.
Variant Calling from SARS-CoV-2 Public Genomes
Variant calling from SARS-CoV-2 public genomes was performed as previously described (Baum et al., 2020a). SARS-CoV-2 com-
plete genome sequences were downloaded from GISAID Nucleotide database (https://www.gisaid.org) on February 4th, 2021. Se-
quences were curated and genetic diversity of the spike-encoding gene was assessed across high quality genome sequences using
custom pipelines. In brief, Blastn was used to align theWuhan-Hu-1 spike nucleotide sequence (accession: MN908947) against each
individual genome. Results were analyzed and presence of the gene was validated if alignment length was greater than 95%with an
identity percentage greater than 70%. Homologous spike protein sequences were extracted, translated and aligned to identify
amino-acid changes with respect to the reference.
Model of RBD-REGN10985-REGN10933-REGN10987
The cryoEM structure of RBD-REGN10933-REGN10987 PDB (6XDG) and the cryoEM structure of RBD-REGN10989-REGN10985
(Figure S4) were superimposed using the software Pymol with the command align for the RBD, where only REGN10933,
REGN10987 and REGN10985 are shown.
Cryo-EM sample preparation and data collection
Fab fragments of REGN10985 and REGN10989 antibodies were digested with FabALACTICA kit (Genovis) and purified by size-
exclusion chromatography. 400 mg of the REGN10985 Fab and 400 mg of REGN10989 Fab were mixed with 200 mg of SARS-
CoV-2 RBD and incubated on ice for 30 min before being injected into a Superdex 200 increase gel filtration column equilibrated
to 50mMTris pH 7.5, 150mMNaCl. Peak fractions containing the REGN10985 Fab - REGN10989 Fab - RBD complex were collected
and concentrated using a 10 kDa MWCO centrifugal filter (Amicon). For cryo-EM grid preparation, the protein sample was diluted to
1.5mg/mL and 0.15%PMAL-C8 amphipol was added. 3.5 mL of protein was deposited onto a freshly plasma cleanedUltrAufoil grid
(1.2/1.3, 300 mesh). Excess solution was blotted away with filter paper for 4 s at blotting force 0, and plunge frozen into liquid ethane
using a Vitrobot Mark IV (Thermo Fisher). The grid was loaded into a Titan Krios (Thermo Fisher) equipped with a K3 detector (Gatan)Cell 184, 1–13.e1–e7, July 22, 2021 e6
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dose rate of 15 electrons per pixel per second was used and each movie was 2 s, corresponding to a total dose of 40 electrons
per Å2.
Cryo-EM data processing
All cryo-EM data processing was carried out using cryoSPARC v2.14.21 (Punjani et al., 2017). The movies were aligned using patch
motion correction and patch CTF estimation. An initial set of particles picked using blob picker were subjected to 2D classification to
generate templates for template picking. 5.5 million particles picked by template picking were subjected to multiple rounds of 2D
classification to remove unbound Fabs and particles containing an incomplete complex, resulting in 607,309 ‘good’ complex parti-
cles. Ab initio reconstruction with 6 classes generated a single class containing 146,054 particles that corresponded to the full
REGN10985 Fab - REGN10989 Fab - RBD complex. Non-uniform refinement of the particles in this class followed by local refinement
resulted in a 3.3 Å resolution (FSC = 0.143) map that was used for model building. Into this map, we manually placed models of the
RBD (taken from PDB code 6M17) and the two Fabs (taken from prior Regeneron antibody structures). These models were then
manually rebuilt using Coot and real-space refined against the map using Phenix (Emsley et al., 2010; Liebschner et al., 2019).
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Supplemental figures
Figure S1. Cryo-EM structure of RBD-REGN10989-REGN10985 in surface representation, related to Figure 2
RBD is in white, REGN10985 in green and REGN19089 in orange.
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Figure S2. Viral load and longitudinal frequencies of S477N in SARS-CoV-2-positive samples from hospitalized patients, related to Figure 5
Viral load was determined by quantitative RT-PCR. Variant frequencies are indicated by the black line as percent of reads with nSNPs relative to total number of
covering reads. Histograms show total (blue) and mutated (magenta) read coverage at variant position.
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Figure S3. Viral load and longitudinal frequencies of S477N in SARS-CoV-2-positive samples from non-hospitalized patients, related to
Figure 6
Viral load was determined by quantitative RT-PCR. Variant frequencies are indicated by the black line as percent of reads with nSNPs relative to total number of
covering reads. Histograms show total (blue) and mutated (magenta) read coverage at variant position.
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Figure S4. Clinical variant neutralization by the REGEN-COV combination and individual antibodies, related to Figures 5 and 6
Variants identified in two ormore samples from at least one patient in either the hospitalized or outpatient trial were assessed for impact on neutralization potency.
A) Neutralization curves and B) Fold-change decrease versus parental D614G virus. *The N501Y variant was used to substitute for N501T.
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